Renalytix AI Company Overview
About Renalytix AI
Renalytix AI (NASDAQ:RNLX) specializes in the development of artificial intelligence (AI)-enabled clinical diagnostics for kidney disease. The company focuses on leveraging AI and machine learning technologies to improve diagnostic accuracy, patient outcomes, and healthcare costs related to chronic kidney disease (CKD) management. Their flagship project includes the KidneyIntelX platform, designed to provide early detection and prognostic prediction of kidney disease progression and treatment efficacy, thus enabling personalized care plans for patients. Renalytix AI aims to transform CKD management through innovative solutions that offer both clinical and economic benefits. By collaborating with healthcare providers, Renalytix AI supports the advancement of precision medicine in nephrology and promotes a proactive approach to kidney health.
Snapshot
Operations
Produtos e/ou serviços de Renalytix AI
- KidneyIntelX is a diagnostic tool aimed at predicting chronic kidney disease progression.
- Partnerships with leading healthcare institutions to integrate kidney disease predictive analytics into clinical practice.
- Collaboration with pharmaceutical companies for renal disease drug development.
- Developing AI-driven clinical laboratory services for kidney health monitoring.
- Expanding the KidneyIntelX platform to additional markers and indications related to kidney health.
- Working on regulatory approvals and reimbursement pathways for broader access to their diagnostics.
equipe executiva do Renalytix AI
- Mr. James R. McCullough M.B.A.CEO & Chairman
- Mr. Fergus FlemingCTO & Executive Director
- Mr. Howard B. Doran Jr.President
- Mr. Joel R. Jung MBAInterim CFO & Principal Accounting Officer
- Dr. Michael J. Donovan M.D., Ph.D.Chief Medical Officer
- Mr. Salim Gulamabbas Hamir F.C.A.Company Secretary